Showing results (81-90 of 408) with videos related to
Sort By:
Pageof 41
American Journal of Hematology|February 24, 2017
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapyAllison Rosenthal, Amylou C Dueck, Stephen Ansell, et al.British Journal of Haematology|August 31, 2019
Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomesJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphomaThomas E Witzig, Christine A White, Leo I Gordon, et al.American Journal of Hematology|March 7, 2016
Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myelomaJohn A Lust, Martha Q Lacy, Steven R Zeldenrust, et al.The Journal of Biological Chemistry|April 2, 2011
GLI2 transcription factor mediates cytokine cross-talk in the tumor microenvironmentSherine F Elsawa, Luciana L Almada, Steven C Ziesmer, et al.Leukemia & Lymphoma|May 24, 2011
Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference reportThomas E Witzig, Paul Fishkin, Leo I Gordon, et al.International Journal of Dermatology|July 9, 2002
Treatment of late-stage Sézary syndrome with 2-ChlorodeoxyadenosineSaskia A Bouwhuis, Rokea A el-Azhary, Marian T McEvoy, et al.Blood|November 17, 2007
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphomaLinfeng Chen, Stefano Monti, Przemyslaw Juszczynski, et al.The Journal of Clinical Investigation|March 20, 2012
IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphomaZhi-Zhang Yang, Deanna M Grote, Steven C Ziesmer, et al.Cancer Biotherapy & Radiopharmaceuticals|November 6, 2007
Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphomaChristos Emmanouilides, Thomas E Witzig, Gregory A Wiseman, et al.Pageof 41